Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis

被引:12
|
作者
Alosaimi, Fahad D. [1 ]
AlMulhem, Alaa [2 ]
AlShalan, Hanan [2 ]
Alqazlan, Mohammad [3 ]
Aldaif, Abdulgader [4 ]
Kowgier, Matthew [5 ]
Balasundaram, Janooshsheya [6 ]
Sockalingam, Sanjeev [6 ,7 ]
机构
[1] King Saud Univ, Dept Psychiat, Riyadh, Saudi Arabia
[2] King Saud Univ, Coll Med, Riyadh, Saudi Arabia
[3] King Faisal Specialist Hosp & Res Ctr, Dept Med Hlth, Riyadh, Saudi Arabia
[4] King Saud Univ, Dept Neurol, Riyadh, Saudi Arabia
[5] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
[6] Univ Hlth Network, Ctr Mental Hlth, Toronto, ON, Canada
[7] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
来源
关键词
multiple sclerosis; adherence; depression; attachment style; culture; MORTALITY; SEVERITY; DEPRESSION; PREVALENCE; VALIDITY; CARE; TOOL;
D O I
10.2147/PPA.S129678
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Our aim was to identify the impact of psychosocial predictors, specifically relationship style, depressive symptoms, anxiety symptoms, cognitive impairment, and culturespecific disease beliefs, on treatment adherence for multiple sclerosis (MS) patients. Methods: In this cross-sectional observational study, patients from two MS clinics in Saudi Arabia completed self-reported questionnaires focused on MS treatment adherence, physical symptom burden, relationship style, cultural beliefs, depressive symptoms, anxiety, and cognitive impairment. Results: A total of 163 MS patients participated, 81.6% of them were female, and the mean age of the patients was 31.6 years. Mean patient-reported adherence to their MS treatment regimen was 79.47%+/- 25.26%. Multivariate linear regression analysis only identified patients' belief that their MS was due to "supernatural" forces as being significantly negatively associated with MS medication adherence. Conclusion: This study demonstrates the importance of cultural interpretations to MS medication adherence in comparison to psychosocial factors. Education and family involvement in the treatment planning may address this issue and warrant further research.
引用
下载
收藏
页码:513 / 518
页数:6
相关论文
共 50 条
  • [1] Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
    Zanga, Gisela
    Drzewiscki, Estefania
    Tagliani, Paula
    Smietniansky, Maximiliano
    Rojas, Maria M. Esnaola y
    Caruso, Diego
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [2] Adherence to Disease-Modifying Therapies for Multiple Sclerosis
    Higuera, Lucas
    Carlin, Caroline S.
    Anderson, Sarah
    Journal of Managed Care & Specialty Pharmacy, 2016, 22 (12): : 1394 - 1401
  • [3] Adherence to disease-modifying therapies in patients with multiple sclerosis
    Koltuniuk, Aleksandra
    Rosinczuk, Joanna
    PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 1557 - 1565
  • [4] Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
    Lugaresi, Alessandra
    Rottoli, Maria Rosa
    Patti, Francesco
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (09) : 1029 - 1042
  • [5] Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low
    Wong, Janice
    Gomes, Tara
    Mamdani, Muhammad
    Manno, Michael
    O'Connor, Paul W.
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2011, 38 (03) : 429 - 433
  • [6] Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario Is Low
    Wong, Janice
    Gomes, Tara
    Mamdani, Muhammad
    Manno, Michael
    O'Connor, Paul W.
    NEUROLOGY, 2011, 76 (09) : A465 - A465
  • [7] Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations
    Evans, Charity
    Marrie, Ruth Ann
    Zhu, Feng
    Leung, Stella
    Lu, Xinya
    Kingwell, Elaine
    Zhao, Yinshan
    Tremlett, Helen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (06) : 702 - 711
  • [8] Disease-modifying therapies for multiple sclerosis
    De Angelis, Floriana
    John, Nevin A.
    Brownlee, Wallace J.
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 363
  • [9] Multiple sclerosis and disease-modifying therapies
    Minen, Mia T.
    Karceski, Steven
    NEUROLOGY, 2011, 77 (04) : E26 - E26
  • [10] Disease-modifying therapies for multiple sclerosis
    John R. Corboy
    Douglas S. Goodin
    Elliot M. Frohman
    Current Treatment Options in Neurology, 2003, 5 (1) : 35 - 54